Tag: HNC

Enfortumab Vedotin Elicits Compelling Data in Head and Neck Cancer

Antitumor activity, tolerability, and a manageable safety profile were observed with enfortumab vedotin (Padcev) monotherapy among patients with heavily pretreated head and neck cancer (HNC) in the phase 2 EV-202 study (NCT04225117).1 With a median follow-up of 9.33 months, the overall response rate (ORR) was 23.9% (n = 11; 95%…

Continue Reading Enfortumab Vedotin Elicits Compelling Data in Head and Neck Cancer

Bioinformatic Technician at Newcastle University

Company description: We are a world class research-intensive university. We deliver teaching and learning of the highest quality. We play a leading role in economic, social and cultural development of the North East of England. Attracting and retaining high-calibre people is fundamental to our continued success. Job description: The Role…

Continue Reading Bioinformatic Technician at Newcastle University

Bioinformatics Technician, Patrick G Johnston Centre for Cancer Research Job in Belfast – Queen’s University Belfast

Bioinformatics Technician, Patrick G Johnston Centre for Cancer Research School of Medicine, Dentistry & Biomedical Sciences (MDBS)Vacancy Number: 23/110816Duration: Fixed Term until 31/10/2024Hours: Full-timeSalary: £30,619 per annum The School of Medicine, Dentistry & Biomedical Sciences (MDBS) at Queen’s University Belfast, is currently seeking to appoint an exceptional candidate to the…

Continue Reading Bioinformatics Technician, Patrick G Johnston Centre for Cancer Research Job in Belfast – Queen’s University Belfast

Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting

BEIJING–(BUSINESS WIRE)–Latest data of InnoCare’s robust oncology pipeline were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Poster Presentation 1: Phase I results of gunagratinib (ICP-192), a highly selective irreversible FGFR 1-4 inhibitor in patients with head and neck cancer (HNC) harboring FGF/FGFR gene aberrations Abstract…

Continue Reading Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting